Trial Information
Retrospective Study of Molecular Predictors of Sensitivity and Resistance to Pemetrexed in Advanced Non-Small Cell Lung Cancer
Inclusion Criteria:
- Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor
tissue available at our institution
- Patients treated with single agent pemetrexed for metastatic disease
- Availability of full clinical data
Exclusion Criteria:
- Cytological diagnosis of advanced Non-small cell lung cancer
- Lack of tumor tissue at our institution
- Lack of full clinical data
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Association of each biomarker with treatment outcome in terms of response rate, time to progression, overall survival.
Outcome Time Frame:
one year
Safety Issue:
No
Principal Investigator
Armando SANTORO, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Istituto Clinico Humanitas
Authority:
Italy: Ministry of Health
Study ID:
ONC/OSS-02/2010
NCT ID:
NCT01193959
Start Date:
September 2010
Completion Date:
September 2011
Related Keywords:
- Non-Small Cell Lung Cancer (NSCLC)
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms